Ogsiveo

News

Merck puts a price on its SpringWorks takeover bid

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.

News

Merck confirms its interest in buying SpringWorks

Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.

News

FDA okays first therapy for desmoid tumours from SpringWorks

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non

Merck puts a price on its SpringWorks takeover bid

Merck confirms its interest in buying SpringWorks

FDA okays first therapy for desmoid tumours from SpringWorks

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks